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Objective: Precision medicine drug therapy seeks to maximize efficacy and minimize harm for 
individual patients. This will be difficult if drug response and side effects are positively associated, 
meaning that patients likely to respond best are at increased risk of side effects. We applied joint 
longitudinal–survival models to evaluate associations between drug response (longitudinal out-
come) and the risk of side effects (survival outcome) for patients initiating type 2 diabetes therapy.
Study design and setting: Participants were randomized to metformin (MFN), sulfo-
nylurea (SU), or thiazolidinedione (TZD) therapy in the A Diabetes Outcome Progression 
Trial (ADOPT) drug efficacy trial (n=4,351). Joint models were parameterized for 1) cur-
rent HbA1c response (change from baseline in HbA1c) and 2) cumulative HbA1c response 
(total HbA1c change).
Results: With MFN, greater HbA1c response did not increase the risk of gastrointestinal events 
(HR per 1% absolute greater current response 0.82 [95% CI 0.67, 1.01]; HR per 1% higher 
cumulative response 0.90 [95% CI 0.81, 1.00]). With SU, greater current response was associ-
ated with an increased risk of hypoglycemia (HR 1.41 [95% CI 1.04, 1.91]). With TZD, greater 
response was associated with an increased risk of  edema (current HR 1.45 [95% CI 1.05, 2.01]; 
cumulative 1.22 [95% CI 1.07, 1.38]) but not fracture.
Conclusion: Joint modeling provides a useful framework to evaluate the association between 
response to a drug and the risk of developing side effects. There may be great potential for 
widespread application of joint modeling to evaluate the risks and benefits of both new and 
established medications.
Keywords: diabetes mellitus, type 2, drug-related side effects, HbA1c, hypoglycemia, joint model, 
precision medicine, thiazolidinediones, metformin, sulfonylurea compounds, ADOPT, edema
Plain language summary
Purpose of study: An overlooked question in precision / stratified medicine and when evaluating 
new medications is: are the benefits and risks of a drug associated? Joint longitudinal-survival 
models can be applied to answer this question when, as in type 2 diabetes, drug response is 
measured by a longitudinal biomarker (HbA1c) and risks of side-effects can be represented as 
a time-to-event outcome.
What did we do and find? We used joint longitudinal–survival models to show novel asso-
ciations between the benefit of greater drug response and the risk of common side effects for 
three glucose-lowering medications for patients with type 2 diabetes. Greater drug response 
was associated with an increased risk of hypoglycemia with sulfonylureas and edema with 
thiazolidinediones. In contrast, there was no evidence of an increased risk of gastrointestinal 
side effects with metformin.
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What do the findings mean? Joint models provide a novel, 
flexible, and robust approach to study the associations between the 
risks and benefits of drug therapy. Precision/stratified medicine 
studies seeking to identify patients or subgroups likely to respond 
well to a drug should also evaluate whether the same patients are 
at increased risk of side effects.
Introduction
There is an increasing interest in applying a precision medi-
cine approach to select the most appropriate drug for a patient 
or subgroup of patients, in order to either improve response or 
reduce side effects.1,2 An important but overlooked question, 
particularly if side effects are a result of the primary phar-
macological effect of the drug, is whether the patients most 
likely to benefit are also at greatest risk of side effects. Type 2 
diabetes is an ideal candidate for precision medicine, as there 
are many drug options to lower blood glucose (as measured by 
HbA1c), but each drug has a different mechanism of action 
and specific side effects. However, the association between 
HbA1c response and side effects is unknown for all drug 
options. If patients likely to have a greater HbA1c response 
to a specific drug are also at increased risk of side effects, 
this may limit the clinical utility of any precision approach 
to type 2 diabetes therapy.
To date, no robust framework has been proposed to 
evaluate the association between drug response and risk 
of side effects. In type 2 diabetes, HbA1c is measured 
repeatedly over time (a longitudinal process), while side 
effect risk can be modeled as a time-to-event process. In 
this scenario, joint longitudinal–survival modeling is the 
preferred approach to evaluate the association between both 
processes.3–6 Joint models attempt to capture the true, unob-
served, longitudinal trajectory (in reality, HbA1c is mea-
sured intermittently and is subjected to measurement error 
from random noise and biological variation). This means 
that joint models can reduce bias and improve efficiency 
compared with simpler approaches.5,7 Joint models have 
been applied in many diseases including recently in type 1 
diabetes (autoantibodies and time to disease onset),8–11 but 
not to our knowledge in type 2 diabetes, or more broadly 
to evaluate the association between drug response and the 
risk of side effects.
In this study, we applied joint modeling to evaluate the 
association between drug response and the risk of established 
side effects for three widely used type 2 diabetes drugs and, 
thus, further evaluate the potential for precision drug therapy 
in type 2 diabetes.
Methods
Overview
Our aim was to understand whether the degree of glycemic 
response to three common glucose-lowering drugs altered 
the risk of developing a side effect. To answer this ques-
tion, we examined the association between the following 
two outcomes: 1) HbA1c response (as measured by change 
from baseline in HbA1c) and 2) risk of developing a side 
effect (gastrointestinal [GI] events, hypoglycemia, edema, 
and fracture).
setting and design
We used individual participant level data from A Diabetes Out-
come Progressing Trial (ADOPT) randomized trial,12 accessed 
through the Clinical Trial Data Transparency Portal under 
approval from GlaxoSmithKline (GSK) (Proposal-930).13 
ADOPT was a prospective head-to-head drug trial includ-
ing treatment-naive participants with type 2 diabetes who 
were randomized to metformin (MFN), the sulfonylurea 
(SU) glyburide, or the thiazolidinedione (TZD) rosiglitazone 
(n=4,351 participants). The aim of ADOPT was to evaluate 
the long-term efficacy of TZD therapy compared to SU and 
MFN, and the primary outcome was time to therapy failure 
(confirmed fasting plasma glucose ≥180 mg/dL). Study visits 
were every 2 months in year 1, then every 3 months up to 
5 years. Clinically determined adverse events were recorded 
at each study visit, including GI events, hypoglycemia, edema, 
and fracture. Biomarkers including HbA1c were recorded 
at each visit. ADOPT participants in the intention to treat 
population with a valid baseline HbA1c were eligible for 
our study. Participants were censored if they reached the 
trial primary endpoint of glycemic failure, trial-recorded 
study withdrawal, or at 5 years after starting therapy as in the 
ADOPT main analysis.
study outcomes
Our time-to-event outcomes were the first occurrence of 
four established drug-specific side effects, over a 5-year 
period. For MFN, the outcome of interest was a GI event, 
for SU, it was hypoglycemia (patient self-reported), and 
for TZD, we evaluated edema and bone fractures.12 Each 
drug and side effect combination was analyzed separately. 
We excluded patients with a pre-trial history of edema 
from the edema analysis (6% of patients), but pre-trial 
hypoglycemia, GI, and fracture records were not avail-
able to do the same for other side effects. Due to the high 
number of GI events, we repeated the GI analysis restricted 
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to only moderate/severe and severe events as sensitivity 
analysis. The longitudinal outcome of interest was HbA1c 
response as measured by change from baseline in HbA1c 
(HbA1c at each study visit [%] – baseline HbA1c [%]). 
Throughout HbA1c percentages refer to absolute values 
rather than  percentage changes. To test the specificity of 
our findings, we repeated the analysis for each side effect 
for the other drugs.
statistical analysis
We used a joint model with two parameterizations (Models 
1 and 2) and two standard time-to-event models (Models 3 
and 4), for comparison, to evaluate the association between 
HbA1c response and the risk of developing a side effect. 
A fundamental difference between each model was in 
the method to estimate HbA1c response, as illustrated in 
Figure 1. Each side effect was evaluated separately, and 
the same modeling approach was applied for each side 
effect. Participants were followed up for up to 5 years 
from randomization. As we were assessing the association 
between side effects and response, all participants required 
at least one pre-side effect HbA1c measure (meaning that 
participants with very early side effects were excluded: 
4% of participants with edema, 3% of participants with 
fracture, 20% of participants with hypoglycemia, and 12% 
of participants with GI events). All models were adjusted 
for baseline HbA1c.14 Model setups were as follows.
Joint longitudinal–survival models
We used a maximum likelihood joint longitudinal–survival 
model to simultaneously assess the association between HbA1c 
response (longitudinal process) and the risk of developing a 
side effect (survival process). The joint model consisted of the 
following two parts: a longitudinal submodel and a survival sub-
model linked through shared subject-specific random effects.6
In the general survival submodel, the hazard for patient 
i (h
i
(t)) can be represented as
h
i
(t) = h
0 
(t) exp (w
i
T γ + αm
i
(t))
where h
0 
(t) is the baseline hazard, w
i
 are baseline covariates, 
γ are regression coefficients, m
i
(t) is the “true, unobserved” 
longitudinal biomarker (estimated from the longitudinal 
submodel), and α quantifies the association between the 
longitudinal biomarker and the time-to-event process.6
We derived m
i
(t) from the observed HbA1c response data 
using a linear mixed effects model with a nonlinear term for 
time (as HbA1c response is typically nonlinear):
y
i
(t) = m
i
(t) + ε
i
 (t)
= β
0
 + β
1
N(t
i
)
1
 + β
2
N(t
i
)
2
 + β
3
 Baseline HbA1c + b
i0
 + b
i1
N(t
i
)
1
 
+ b
i2
N(t
i
)
2
 + 
 
ε
i
 (t)
where y
i
 is the observed HbA1c change from baseline 
and m
i
 is the “true”, unobserved HbA1c change from 
Figure 1 approaches to estimating hba1c (%) response.
Notes: Model 1: estimate current hba1c response using a joint model (red line with black dotted 95% Cis). Model 2: estimate cumulative hba1c response using a joint 
model (gray-shaded area). Model 3: carry forward the most recently observed value of hba1c response until the next measurement (lOCF approach, black step function). 
Model 4: take the observed hba1c response at a single time point of 6 months (blue line).
Abbreviation: lOCF, last observation carried forward.
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baseline. N(t
i
)
1
 and N(t
i
)
2
 denote the basis for a nonlinear 
natural cubic spline of time with one internal knot at the 
50th percentile of follow-up time (included in both the 
fixed and random effect parts of the longitudinal HbA1c 
submodel), b
i
 is a vector of subject-specif ic random 
effects, b
i
~ N (O, ) where  is the unstructured covariance 
matrix of random effects, ε
i
 is the vector of residuals, and 
ε
i
 ~ N(O,s2), where s2 is the covariance matrix of the residu-
als.6 For models of hypoglycemia with MFN and edema with 
SUs, we used a linear term for the random effect of time to 
achieve model convergence.
Model 1: joint model current value (JMcv). To assess 
the association between the current value of HbA1c 
response and the risk of side effects (the standard formu-
lation of the joint model), we incorporated m
i
 from the 
longitudinal submodel as a time-dependent covariate in 
the survival submodel:
h
i
(t) = h
0 
(t) exp {γ
0
Baseline HbA1c + αm
i 
(t)}
Model 2: joint model cumulative HbA1c (JMcum). To 
evaluate whether the risk of side effects was associated with 
total rather than current HbA1c response, we specified a 
second formulation of the joint model to assess the asso-
ciation between cumulative HbA1c response (total HbA1c 
response estimated as area under the curve) and the risk 
of side effects, by including ſ  t
0
 m
i
(s) ds, the integral of the 
longitudinal HbA1c response trajectory up to time t, in the 
time-to-event submodel:6,15
h
i
(t) = h
0 
(t) exp {γ
0
Baseline HbA1c + α 
 
ſ  t
0
 m
i
(s) ds}
For Models 1 and 2, we used a B-spline with five internal 
knots to flexibly model the baseline hazard function. We 
examined the fit of submodels using residual plots. Models 
1 and 2 were fitted using the JM package in R.16
Model 3: last observation carried forward (LOCF) 
analysis. We included observed HbA1c response (HbA1c 
at time t – baseline HbA1c) as a time-dependent covariate 
in a Cox proportional hazards model. This approach does 
not correct for measurement error and assumes that HbA1c 
response is constant between measurements. HRs represent 
the increased risk of a side effect for a 1-unit (%) absolute 
increase in the most recent value of HbA1c change from 
baseline at time t.
Model 4: single estimate of HbA1c response at 6 months 
(6mR). We evaluated the association between HbA1c 
response at 6 months and the subsequent risk of developing 
a side-effect. In this two-stage approach, we first estimated 
a single estimate of HbA1c response as a change score at 
6 months. In the second stage, we used this estimate as the 
exposure in a Cox hazards survival model with delayed entry 
to 6 months. Participants who developed a side effect prior to 
6 months or had no HbA1c record at 6 months were excluded 
from this analysis.
Results
The most common side effects were GI side effects with 
MFN (37%), followed by hypoglycemia with SU therapy 
(26%). TZD side effects were less common (edema 13% 
and fracture 7%; Table 1). The median follow-up was 
greater than 2.5 years in each cohort (for other participant 
characteristics, refer Table S1). Each side effect occurred 
more frequently on these therapies than on the comparator 
drugs (Table S2).
Joint model associations between hba1c 
response and risk of side effects
gi events
With MFN, we found consistent evidence for an association 
between greater HbA1c response and reduced risk of a GI 
side effect (Figure 2A). We observed a similar association 
for moderate/severe GI events (20% of patients) and no 
association for severe GI events (3% of patients) (Table S3). 
We found no evidence of an association with TZDs and SUs 
(Tables 2 and S3).
hypoglycemia
With SUs, we found that greater current HbA1c response 
was associated with an increased risk of hypoglycemia 
Table 1 Participant numbers and study follow-up for each primary drug: side effect cohort (Models 1–3)
Metformin – GI SU – hypo TZD – edema TZD – fracture
number of participants 1,200 1,052 1,241 1,311
number of events (%) 440 (37%) 270 (26%) 164 (13%) 88 (7%)
Baseline hba1c (%) 7.3 (6.7; 7.9) 7.3 (6.7; 7.9) 7.3 (6.7; 7.9) 7.3 (6.7; 7.9)
number of recorded hba1c 13 (6; 19) 12 (5; 19) 18 (9; 20) 18 (10; 21)
study follow-up (years) 2.8 (1.0; 4.2) 2.5 (0.9; 4.2) 4.0 (1.8; 4.7) 4.0 (2.1; 4.7)
Note: Data are median (iQr) unless stated (refer Table s4 for participants included in Model 4).
Abbreviations: gi, gastrointestinal; sU, sulfonylurea; TZD, thiazolidinedione.
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(Model 1: JMcv; Figure 2B). We found no evidence for an 
association between the risk of hypoglycemia and cumula-
tive HbA1c response (Model 2: JMcum). With TZD therapy, 
although the absolute risk of hypoglycemia was much 
lower than with SU therapy (8 vs 26%), greater current 
and cumulative HbA1c responses were associated with an 
increased risk of hypoglycemia. There was no evidence of 
an association between response and hypoglycemia with 
MFN (Table 2).
Edema
With TZDs, greater current (Model 1: JMcv) and cumulative 
(Model 2: JMcum) HbA1c responses were associated with an 
increased risk of edema (Figure 2C). We found no evidence 
of an association between HbA1c response and the risk of 
edema with MFN and SUs (Table 2).
Fracture
With TZDs, we found no evidence for an association between 
HbA1c response and the risk of a fracture (Figure 2D). There 
was also no evidence of an association with MFN and SUs 
(Tables 2).
associations using standard time-to-
event approaches
Results using the LOCF approach (Model 3: LOCF) were 
generally consistent with those from the current value 
joint models (Model 1: JMcv) (Table 2 and Figure 2). The 
exception was for TZDs and edema, for which, in contrast 
to the joint model, we found no evidence of an associa-
tion using the LOCF model. Using Model 4: 6mR (where 
HbA1c response was estimated from a single 6 month 
value), we found no evidence of any association between 
Figure 2 HRs for the association between HbA1c response and the risk of a drug-specific side effect (models 1–3).
Notes: hrs (95% Ci) represent the increase in the risk of side effect for a 1% greater absolute hba1c response. a hr of greater than 1 indicates an increased risk of side 
effect with greater hba1c response.
Abbreviations: JMcum, joint model cumulative hba1c; JMcv, joint model current value; lOCF, last observation carried forward; MFn, metformin; sU, sulfonylurea; TZD, 
thiazolidinedione.
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HbA1c response and the risk of side effects except for GI 
events with MFN (HR per 1% absolute increase in 6-month 
HbA1c response, 0.74 [95% CI 0.60, 0.91], Table S5).
Discussion
Our study shows that joint modeling can be a useful approach 
for evaluating associations between the benefits and risks of 
drug therapy. Using joint models for longitudinal and time-
to-event data, we were able to show important differences 
in the associations between drug response and the risk of 
established side effects for three widely used type 2 diabetes 
drugs. We also found differences in the association between 
each of current and cumulative drug response and the risk 
of side-effects, suggesting underlying differences in the 
nature of associations for different drugs. Our results have 
implications for any precision medicine approach to type 2 
diabetes therapy. More generally, they highlight the potential 
for the widespread application of joint longitudinal–survival 
modeling to evaluate the benefits and risks of both new and 
established medications.
advantages and disadvantages of joint 
models to evaluate the association 
between drug response and risk of side 
effects
We found a key advantage of joint models to be their flexibil-
ity. Different specifications of the joint model gave important 
additional insight into the underlying nature of associations 
between HbA1c response and side effects. These insights 
fitted with what is known about the pharmacological action 
of the different drugs. Current, but not cumulative, HbA1c 
response was associated with an increased risk of hypogly-
cemia with SUs. This is expected as hypoglycemia is a side 
effect related to short-term fluctuations in blood glucose, 
rather than long-term exposure. In contrast, for edema with 
TZDs, which is less likely to relate to short-term fluctuations 
in blood glucose, we observed associations for both current 
and cumulative HbA1c responses.
We also found associations with joint models that were 
missed by simpler approaches. With edema with TZD therapy, 
there was no association using the LOCF approach but a clear 
association using both specifications of the joint model. This 
is likely due to the reduced bias and increased efficiency of 
the joint model compared with the LOCF approach, which 
does not correct for measurement error in the longitudi-
nal HbA1c response.5,7 In general, HRs using the LOCF 
approach had the same direction of association but were 
attenuated compared with those obtained from the current 
value joint model, in keeping with previous comparisons.4,17 
We found that a single measure of HbA1c at 6 months was 
insufficient to show the evidence of an association between 
HbA1c response and side effects, with the exception of GI 
side effects with MFN where the association was consistent 
with the joint model.
There are some settings where joint models may be more 
limited. ADOPT was a large randomized, double-blinded 
trial, and in this dataset, we found joint models to be useful 
to evaluate the association between response and relatively 
common side effects. Increasingly, similar trial datasets are 
Table 2 hrs for the association between hba1c response and risk of side effects (models 1–3)
Side effect Model 1: JMcv Model 2: JMcum Model 3: LOCF
MFn
gi 0.82 (0.67, 1.01), P=0.06 0.90 (0.81, 1.00), P=0.06 0.85 (0.74, 0.96), P=0.01
hypoglycemia 1.01 (0.63, 1.62), P=0.96 1.22 (0.93, 1.60), P=0.15 1.19 (0.88, 1.60), P=0.25
Edema 1.16 (0.70, 1.92), P=0.58 1.09 (0.88, 1.36), P=0.42 1.07 (0.74, 1.56), P=0.71
Fracture 0.83 (0.48, 1.44), P=0.51 1.00 (0.78, 1.27), P=0.98 0.98 (0.69, 1.39), P=0.92
sU
gi 0.88 (0.69, 1.11), P=0.28 1.03 (0.92, 1.17), P=0.58 0.90 (0.77, 1.05), P=0.19
hypoglycemia 1.41 (1.04, 1.91), P=0.03 1.09 (0.93, 1.29), P=0.28 1.41 (1.12, 1.77), P=0.003
Edema 1.31 (0.85, 2.02), P=0.23 1.09 (0.87, 1.36), P=0.45 0.87 (0.67, 1.13), P=0.28
Fracture 1.16 (0.70, 1.92), P=0.58 1.09 (0.88, 1.36), P=0.42 1.00 (0.64, 1.58), P=0.68
TZD
gi 1.21 (0.94, 1.55), P=0.13 1.05 (0.93, 1.18), P=0.44 1.04 (0.87, 1.26), P=0.65
hypoglycemia 1.98 (1.25, 3.15), P=0.004 1.37 (1.11, 1.7), P=0.003 1.44 (0.98, 2.12), P=0.07
Edema 1.45 (1.05, 2.01), P=0.03 1.22 (1.07, 1.38), P=0.003 1.01 (0.80, 1.27), P=0.94
Fracture 1.10 (0.72, 1.68), P=0.65 1.09 (0.93, 1.29), P=0.28 1.05 (0.72, 1.52), P=0.81
Notes: hrs (95% Ci) represent the increase in risk of a side effect for a 1% greater absolute hba1c response. a hr of greater than 1 indicates an increased risk of a side 
effect with greater hba1c response.
Abbreviations: gi, gastrointestinal; JMcum, joint model cumulative hba1c; JMcv, joint model current value; lOCF, last observation carried forward; MFn, metformin; sU, 
sulfonylurea; TZD, thiazolidinedione.
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available for researchers to address secondary research ques-
tions.13,18 It may be more challenging to apply joint modeling 
in other datasets. In particular, the potential of recording 
bias should be considered if conducting similar studies in 
electronic health records, although greater sample size may 
offer the opportunity to study rarer side effects. Testing the 
specificity of results to drugs known to cause the side effect 
by comparison with “negative control” drugs may be a use-
ful starting point. Joint models may also be harder to apply 
to study associations between drug response and acute or 
allergic side effects that occur immediately after starting 
therapy. This was apparent in our analysis, as although we 
included over 1,000 participants for each drug, participants 
who developed an early side effect prior to a first on-therapy 
HbA1c were excluded, and this is a particular limitation of 
our analysis of hypoglycemia with SUs. Another limitation 
of the joint modeling framework applied in this study is 
the assumption of a fixed association between longitudinal 
HbA1c and the risk of each side effect. While inspection of 
residual plots indicated that this was an appropriate strategy, 
it is certainly plausible that associations could change with 
therapy duration, and incorporating duration of therapy as 
a time-varying effect within the joint modeling framework 
would be of considerable interest. Similarly, an extension 
of the joint modeling framework to robustly incorporate 
drug dose could yield further insight to complement the 
response:side effect associations evaluated in this study. 
Evaluating the impact of dose is a particular challenge in 
trials of drug efficacy such as ADOPT, as participants could 
be both uptitrated based on reaching glycemic thresholds 
and downtitrated if a randomized medication was poorly 
tolerated.
implications for a precision medicine 
approach to type 2 diabetes therapy
Our findings for the different drugs have implications for 
any future precision medicine approach to type 2 diabetes 
therapy. Greater MFN drug response was not associated 
with an increased risk of GI side effects, and this suggests 
great potential to target therapy if patients likely to have 
greater drug response can be robustly identified.19 However, 
targeting SUs and TZDs to patients may be difficult as good 
responders are likely to be at increased risk of, respectively, 
hypoglycemia and edema. Our findings highlight the vital 
importance of considering both differential drug response 
and the risk of side effects in precision medicine studies, and 
this has been overlooked in previous work.20,21
Our findings do not however preclude a precision medi-
cine approach for SUs and TZDs. Identification of charac-
teristics associated with either, but not both, improved drug 
response or lower risk of side effects may allow the targeting 
of these therapies. Furthermore, decisions on therapy should 
ultimately be informed by absolute rather than relative risks 
of benefit or harm.1 For example, if patients likely to respond 
well to a TZD can be identified, then, a TZD may still be 
an appropriate option for patients whose absolute risk of 
developing a side effect is sufficiently low.
Comparison with other studies
To our knowledge, this is the first evaluation of the associa-
tion between HbA1c response and the risk of side effects for 
any of the three drugs, except for hypoglycemia with SUs. 
Our results for SUs are consistent with previous observa-
tional studies that have examined the association between 
hypoglycemia and achieved on-therapy HbA1c (rather than 
HbA1c response).22,23 In the ACCORD trial, participants 
with the greatest HbA1c response at 4 months had a reduced 
rather than increased risk of hypoglycemia, although this can 
be explained by the fact that, in ACCORD, the participants 
with least initial response were more likely to be on insu-
lin, the therapy with by far the strongest association with 
hypoglycemia.24
In this study, we found an unexpected association between 
greater response to TZD therapy and an increased risk of 
hypoglycemia, but no evidence of an association with MFN 
response, which would have indicated a positive associa-
tion between increased drug response and increased risk of 
hypoglycemia was a more general characteristic of glucose-
lowering therapy. This is an interesting finding for which 
there is no clear biological explanation, and it would be of 
interest to examine whether the association can be replicated 
in other datasets. The association between edema and HbA1c 
response with TZDs is not unexpected as the mechanisms 
underlying both glucose-lowering and fluid retention are 
thought to relate to Peroxisome proliferator-activated recep-
tor gamma (PPAR-g) stimulation.25 With MFN, there is no 
clear biological reason for the association between greater 
HbA1c response and a lower risk of GI events. One possible 
explanation is decreased drug adherence in patients experi-
encing mild GI symptoms prior to the event being recorded.
Future work
There is great potential to apply joint modeling to evaluate the 
association between drug response and the risk of side effects 
for the other drug options in type 2 diabetes and to study drug 
therapy in other diseases. Our findings also suggest a potential 
application of joint modeling as an efficient tool for under-
standing the risk–benefit trade-off at the individual level in 
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drug development.26 For precision medicine, the joint models 
used in this study could be extended to explore clinical fea-
tures and biomarkers associated with drug response, the risk 
of side effects, or both.27,28 Alternative model specifications, 
such as evaluation of the effect of HbA1c response slope,6 
the weighting of cumulative HbA1c effects by recency,15 
the incorporation of multiple longitudinal biomarkers,29 and 
exploration of time-varying drug effects, may provide further 
insight into the nature of associations between response and 
side effects. Similarly, incorporation of robust dose adjust-
ment within the joint modeling framework, for example, test-
ing weighted cumulative drug associations,30,31 could allow 
much greater understanding of the impact of different levels 
of drug exposure on both response and adverse events. Many 
of these are areas of current methodological development; 
a general mathematical presentation of joint modeling for 
simultaneously evaluating risks and benefits of medication 
would be a useful next step.
Conclusion
Joint modeling is a useful and efficient method to evaluate 
associations between continuous drug response and time to 
side effects. Our study suggests the potential for the applica-
tion of joint modeling in both drug development and precision 
medicine research to evaluate the benefits and risks of medi-
cations. In type 2 diabetes, any future precision approach to 
SU and TZD therapy should consider the likely increased risk 
of, respectively, hypoglycemia and edema, if targeting these 
therapies at patients likely to have the greatest drug response.
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